Prostate Cancer

>

Latest News

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

June 4th 2025

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.
FDA OKs Darolutamide in Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

June 3rd 2025

Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC
Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC

June 3rd 2025

Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC
Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC

June 2nd 2025

Video Series
Video Interviews
Podcasts
1 expert in this video
1 expert in this video
1 expert in this video
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

More News